Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Bill would loosen rules on state‑stockpiled abortion medications; testimony sharply divided
Loading...
Summary
SSB 59‑17 would remove strict cost‑recovery limits on state‑purchased mifepristone and misoprostol and allow donation or sale below purchase price, prioritizing distribution to health providers; proponents warned stockpiles will expire, while opponents said the purchase and distribution misuse taxpayer dollars.
Substitute Senate Bill 59‑17 would change how the state stores and distributes a stockpile of medication (mifepristone and misoprostol) purchased in 2023. Staff said the bill removes the statutory requirement that the Department of Corrections sell or distribute the drugs only at cost plus a $5 fee and instead authorizes DOC to obtain payment but not require it; the bill also assigns a supporting role to the Department of Health and prioritizes distribution to providers, including tribal health organizations.
Proponents argued the purchase was a protective public‑health measure and that, absent statutory change, the medication may expire and become unusable. Samantha Grama of the Washington State Women's Commission said the bill is a "simple fix to ensure the legislature's proactive efforts in 2023 can be fully realized." Gabby Nazary of Pro Choice Washington said making the stockpile available to providers will help people with high barriers to access.
Opponents argued the original purchase was improper and that distributing the medications at low or no cost would be an unconstitutional gift of public funds. Eric Lundberg and other faith‑based witnesses framed distribution as morally objectionable. Testimony also raised questions about accounting and transparency for the original purchase and potential for misuse.
The committee closed public testimony and returned to other items without a final vote on Feb. 18.
